The pharmacologic management of cancer pain

ONCOLOGY

Volumn 18, Issue 12, 2004, Pages 1499-1515

  Cherny, Nathan I ^a  

^a SHAARE ZEDEK MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; NARCOTIC AGENT; NARCOTIC ANALGESIC AGENT; OPIATE RECEPTOR;

DRUG ADMINISTRATION; DRUG ADMINISTRATION ROUTE; DRUG EFFECT; DRUG TOLERANCE; HUMAN; METHODOLOGY; NEOPLASM; PAIN; PAIN ASSESSMENT; PALLIATIVE THERAPY; REVIEW;

ANALGESICS; ANALGESICS, OPIOID; DRUG ADMINISTRATION ROUTES; DRUG ADMINISTRATION SCHEDULE; DRUG TOLERANCE; HUMANS; NARCOTICS; NEOPLASMS; PAIN; PAIN MEASUREMENT; PALLIATIVE CARE; RECEPTORS, OPIOID;

EID: 16244368099     PISSN: 08909091     EISSN: 08909091     Source Type: Journal    
DOI: None     Document Type: Review

References (169)

1. World Health Organization: Cancer Pain Relief. Geneva, World Health Organization, 1986.
2. Takeda F: Japanese field-testing of WHO guidelines. PRN Forum 4(3):4-5, 1985.
3. Ventafridda V, Tamburini M, Caraceni A, et al: A validation study of the WHO method for cancer pain relief. Cancer 59(4):850-856, 1987.
4. Walker VA, Hoskin PJ, Hanks GW, et al: Evaluation of WHO analgesic guidelines for cancer pain in a hospital-based palliative care unit. J Pain Symptom Manage 3(3):145-149, 1988.
5. Schug SA, Zech D, Dorr U: Cancer pain management according to WHO analgesic guidelines. J Pain Symptom Manage 5(1):2732, 1990.
6. Goisis A, Gorini M, Ratti R, et al: Application of a WHO protocol on medical therapy for oncologic pain in an internal medicine hospital. Tumori 75(5):470-472, 1989.
7. Grond S, Zech D, Schug SA, et al: Validation of World Health Organization guidelines for cancer pain relief during the last days and hours of life. J Pain Symptom Manage 6(7):411-422, 1991.
8. McNicol E, Strassels S, Goudas L, et al: Nonsteroidal anti-inflammatory drugs, alone or combined with opioids, for cancer pain: A systematic review. J Clin Oncol 22(10): 1975-1992, 2004.
9. Lefkowith JB: Cyclooxygenase-2 specificity and its clinical implications. Am J Med 106(5B):43S-50S, 1999.
10. Enrich EW, Dallob A, De Lepeleire I, et al: Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model. Clin Pharmacol Ther 65(3):336-347, 1999.
11. Hawkey CJ: COX-2 inhibitors. Lancet 353(9149):307-314, 1999.
12. Dickman A, Ellershaw J: NSAIDs: Gastroprotection or selective COX-2 inhibitor? Palliat Med 18(4):275-286, 2004.
13. Makin AJ, Williams R: Acetaminophen induced hepatotoxicity: Predisposing factors and treatments. Adv Intern Med 42:453-483, 1997.
14. Portenoy RK, Foley KM, Inturrisi CE: The nature of opioid responsiveness and its implications for neuropathic pain: New hypotheses derived from studies of opioid infusions [see comments]. Pain 43(3):273-286, 1990.
15. Hanks GW, Forbes K: Opioid responsiveness. Acta Anaesthesiol Scand 41(1 pt2):154-158, 1997.
16. Houde RW, Wallenstein SL, Beaver WT: Evaluation of analgesics in patients with cancer pain, in Lasagna L (ed): International Encyclopedia of Pharmacology and Therapeutics, pp 59-67. New York, Pergamon, 1966.
17. Ripamonti C, Groff L, Brunelli C, et al: Switching from morphine to oral methadone in treating cancer pain. What is the equianalgesic dose ratio? J Clin Oncol 16:3216-3221, 1998.
18. Chemy NJ, Chang V, Frager G, et al: Opioid pharmacotherapy in the management of cancer pain: A survey of strategies used by pain physicians for the selection of analgesic drugs and routes of administration. Cancer 76(7): 1283-1293, 1995.
19. de Stoutz ND, Bruera E, Suarez-Almazor M: Opioid rotation for toxicity reduction in terminal cancer patients. J Pain Symptom Manage 10(5):378-384, 1995.
20. Varvel JR, Shafer SL, Hwang SS, et al: Absorption characteristics of transdermally administered fentanyl. Anesthesiology 70(6):928-934, 1989.
21. Jeal W, Benfield P: Transdermal fentanyl. A review of its pharmacological properties and therapeutic efficacy in pain control. Drugs 53(1):109-138, 1997.
22. Ahmedzai S, Brooks D: Transdermal fentanyl versus sustained-release oral morphine in cancer pain: Preference, efficacy, and quality of life. The TTS-Fentanyl Comparative Trial Group. J Pain Symptom Manage 13(5):254-261, 1997.
23. Donner B, Zenz M, Tryba M, et al: Direct conversion from oral morphine to transdermal fentanyl: A multicenter study in patients with cancer pain. Pain 64(3):527-534, 1996.
24. Payne R, Mathias SD, Pasta DJ, et al: Quality of life and cancer pain: Satisfaction and side effects with transdermal fentanyl versus oral morphine. J Clin Oncol 16(4): 1588-1593, 1998.
25. Kaiko RF, Fitzmartin RD, Thomas GB, et al: The bioavailability of morphine in controlled-release 30-mg tablets per rectum compared with immediate-release 30-mg rectal suppositories and controlled-release 30-mg oral tablets. Pharmacotherapy 12(2):107-113, 1992.
26. Maloney CM, Kesner RK, Klein G, et al: The rectal administration of MS Contin: Clinical implications of use in end stage cancer. Am J Hosp Care 6(4):34-35, 1989.
27. Hanks GW, Conno F, Cherny N, et al: Morphine and alternative opioids in cancer pain: The EAPC recommendations. Br J Cancer 84(5):587-593, 2001.
28. Burton AW, Driver LC, Mendoza TR, et al: Oral transmucosal fentanyl citrate in the outpatient management of severe cancer pain crises: A retrospective case series. Clin J Pain 20(3):195-197, 2004.
29. Loitman JE: Transmucosal fentanyl in ovarian cancer. J Pain Symptom Manage 23(1):5-7, 2002.
30. Hagen NA, Elwood T, Ernst S: Cancer pain emergencies: A protocol for management. J Pain Symptom Manage 14(1):45-50, 1997.
31. Coy le N, Chemy NI, Portenoy RK: Subcutaneous opioid infusions at home. Oncology (Huntingt) 8(4):21-27 (discussion 31-32, 37), 1994.
32. Torre MC: Subcutaneous infusion: Non-metal cannulae vs metal butterfly needles. Br J Community Nurs 7(7):365-369, 2002.
33. Lyss AP: Long-term use of oral transmucosal fentanyl citrate (OTFC) for break through pain in cancer patients (abstract). Proc Am Soc Clin Oncol 16:A144, 1997.
34. Ripamonti C, Bruera E: Current status of patient-controlled analgesia in cancer patients. Oncology (Huntingt) 11(3):373-384 (discussion 384-386), 1997.
35. Cherny N, Ripamonti C, Pereira J, et al: Strategies to manage the adverse effects of oral morphine: An evidence-based report. J Clin Oncol 19(9):2542-2554, 2001.
36. Fallon MT, O'Neill B: Substitution of another opioid for morphine. Opioid toxicity should be managed initially by decreasing the opioid dose [letter, comment]. Br Med J 317(7150):81, 1998.
37. Portenoy RK: Adjuvant analgesic agents. Hematol Oncol Clin North Am 10(1):103-119, 1996.
38. Janjan NA: Radiation for bone metastases: Conventional techniques and the role of systemic radiopharmaceuticals. Cancer 80(8 suppl):1628-1645, 1997.
39. Bates T: A review of local radiotherapy in the treatment of bone metastases and cord compression. Int J Radiat Oncol Biol Phys 23(1):217-221, 1992.
40. Vermeulen SS: Whole brain radiotherapy in the treatment of metastatic brain tumors. Semin Surg Oncol 14(1):64-69, 1998.
41. Sneed PK, Larson DA, Wara WM: Radiotherapy for cerebral metastases. Neurosurg. Clin N Am 7(3):505-515, 1996.
42. Coia LR: The role of radiation therapy in the treatment of brain metastases. Int J Radiat Oncol Biol Phys 23(1):229-238, 1992.
43. Rothenberg ML: New developments in chemotherapy for patients with advanced pancreatic cancer. Oncology (Huntingt) 10(9 suppl): 18-22, 1996.
44. Thatcher N, Anderson H, Betticher DC, et al: Symptomatic benefit from gemcitabine and other chemotherapy in advanced non-small cell lung cancer: changes in performance status and tumour-related symptoms. Anticancer Drugs 6 (suppl 6):39-48, 1995.
45. Lawlor P, Turner K, Hanson J, et al: Dose ratio between morphine and hydromorphone in patients with cancer pain: A retrospective study. Pain 72(1-2):79-85, 1997.
46. Bruera E, Pereira J, Watanabe S, et al: Opioid rotation in patients with cancer pain. A retrospective comparison of dose ratios between methadone, hydromorphone, and morphine. Cancer 78(4):852-857, 1996.
47. Bruera E, Franco JJ, Maltoni M, et al: Changing pattern of agitated impaired mental status in patients with advanced cancer Association with cognitive monitoring, hydration, and opioid rotation. J Pain Symptom Manage 10(4):287-291, 1995.
48. Thomas Z, Bruera E: Use of methadone in a highly tolerant patient receiving parenteral hydromorphone. J Pain Symptom Manage 10(4):315-317, 1995.
49. Galer BS, Coyle N, Pasternak GW, et al: Individual variability in the response to different opioids: Report of five cases. Pain 49(1):87-91, 1992.
50. Fitzgibbon DR, Ready LB: Intravenous high-dose methadone administered by patient controlled analgesia and continuous infusion for the treatment of cancer pain refractory to high-dose morphine. Pain 73(2):259-261, 1997.
51. Ripamonti C, Groff L, Brunelli C, et al: Switching from morphine to oral methadone in treating cancer pain: What is the equianalgesic dose ratio? [see comments]. J 'Clin Oncol 16(10):3216-3221, 1998.
52. Maddocks I, Sornogyi A, Abbott F, et al: Attenuation of morphine-induced delirium in palliative care by substitution with infusion of oxycodone. J Pain Symptom Manage 12(3):182-189, 1996.
53. Vigano A, Fan D, Bruera E: Individualized use of methadone and opioid rotation in the comprehensive management of cancer pain associated with poor prognostic indicators. Pain 67(1):115-119, 1996.
54. Paix A, Coleman A, Lees J, et al: Subcutaneous fentanyl and sufentanil infusion substitution for morphine intolerance in cancer pain management. Pain 63(2):263-269, 1995.
55. Ashby MA, Martin P, Jackson KA: Opioid substitution to reduce adverse effects in cancer pain management. Med J Aust 170(2):68-71, 1999.
56. Hagen N, Swanson R: Strychnine-like multifocal myoclonus and seizures in extremely high- dose opioid administration: Treatment strategies [see comments]. J Pain Symptom Manage 14(1):51-58, 1997.
57. Makin MK, EUershaw JE: Substitution of another opioid for morphine. Methadone can be used to manage neuropathic pain related to cancer [letter, comment]. Br Med J 317(7150):81, 1998.
58. Rossi GC, Leventhal L, Pan YX, et al: Antisense mapping of MOR-1 in rats: distinguishing between morphine and morphine 6beta-glucuronide antinociception. J Pharmacol Exp Ther 281(1):109-114, 1997.
59. Pasternak GW, Standifer KM: Mapping of opioid receptors using antisense oligodeoxynucleotides: Correlating their molecular biology and pharmacology [see comments]. Trends Pharmacol Sci 16(10):344-350,1995.
60. Zadina JE, Kastin AJ, Harrison LM, et al: Opiate receptor changes after chronic exposure to agonists and antagonists. Ann N Y Acad Sci 757:353-361, 1995.
61. Brosen K, Sindrup SH, Skjelbo E, et al: Role of genetic polymorphism in psychophar macology-An update. Psychopharmacol Ser 10:199-211, 1993.
62. Fromm MF, Hofmann U, Griese EU, et al: Dihydrocodeine: A new opioid substrate for the polymorphic CYP2D6 in humans. Clin Pharmacol Ther 58(4):374-382, 1995.
63. Heiskanen T, Olkkola KT, Kalso E: Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Clin Pharmacol Ther 1998; 64(6):603-611, 1998.
64. Kirkwood LC, Nation RL, Sornogyi AA: Characterization of the human cytochrome P450 enzymes involved in the metabolism of dihydrocodeine. Br J Clin Pharmacol 44(6):549-555, 1997.
65. Poulsen L, Brosen K, Arendt-Nielsen L, et al: Codeine and morphine in extensive and poor metabolizers of sparteine: Pharmacokinetics, analgesic effect and side effects. Eur J Clin Pharmacol 51(3-4):289-295, 1996.
66. Sindrup SH, Poulsen L, Brosen K, et al: Are poor metabolisers of sparteine/ debrisoquine less pain tolerant than extensive metabolisers? Pain 53(3):335-339, 1993.
67. Sindrup SH, Brosen K: The pharmaco-genetics of codeine hypoalgesia. Pharmacogenetics 1995; 5(6):335-346, 1995.
68. McDonald P, Graham P, Clayton M, et al: Regular subcutaneous bolus morphine via an indwelling cannula for pain from advanced cancer. Palliative Medicine 5:323-329, 1991.
69. Drexel H, Dzien A, Spiegel RW, et al: Treatment of severe cancer pain by low-dose continuous subcutaneous morphine. Pain 36(2):169-176, 1989.
70. Fallon M, O'Neill B: ABC of palliative care Constipation and diarrhoea. Br Med J 315(7118):1293-1296, 1997.
71. Vainio A, Ollila J, Matikainen E, et al: Driving ability in cancer patients receiving long-term morphine analgesia. Lancet 346(8976):667-670, 1995.
72. Portenoy RK: Management of common opioid side effects during long-term therapy of cancer pain. Ann Acad Med Singapore 23(2):160-170, 1994.
73. Wells CI, Lipton S, Lahuerta J: Respiratory depression after percutaneous cervical anterolateral cordotomy in patients on slow release oral morphine [letter]. Lancet 1(8379):739, 1984.
74. Mercadante S: Pathophysiology and treatment of opioid-related myoclonus in cancer patients. Pain 74(1):5-9, 1998.
75. Watanabe S, Bruera E: Corticosteroids as adjuvant analgesics. J Pain Symptom Manage 9(7):442-445, 1994.
76. Rousseau P: The palliative use of high-dose corticosteroids in three terminally ill patients with pain. Am J Hosp Palliat Care 18(5):343-346, 2001.
77. Devor M, Govrin-Lippmann R, Raber P: Corticosteroids suppress ectopic neural discharge originating in experimental neuromas. Pain 22(2):127-137, 1985.
78. Sorensen S, Helweg-Larsen S, Mouridsen H, et al: Effect of high-dose dex-amethasone in carcinomatous metastatic spinal cord compression treated with radiotherapy: A randomised trial. Eur J Cancer 30A(1):22-27, 1994.
79. Twycross R: The risks and benefits of corticosteroids in advanced cancer. Drug Saf 11(3):163-178, 1994.
80. Ellershaw JE, Kelly MI: Corticosteroids and peptic ulceration. Palliat Med 8(4):313-319, 1994
81. McQuay HJ, Tramer M, Nye BA, et al: A systematic review of antidepressants in neuropathic pain. Pain 68(2-3):217-227, 1996.
82. Mattia C, Paoletti F, Coluzzi F, et al: New antidepressants in the treatment of neuropathic pain. A review. Minerva Aneslesiol 68(3):105-114, 2002.
83. Bennett MI, Simpson KH: Gabapentin in the treatment of neuropathic pain. Palliat Med 18(1):5-11,2004.
84. Galer BS, Harle J, Rowbotham MC: Response to intravenous lidocaine infusion predicts subsequent response to oral mexiletine: A prospective study. J Pain Symptom Manage 12(3):161-167, 1996.
85. Lipman AG: Analgesic drugs for neuropathic and sympathetically maintained pain. Clin GeriatrMed 12(3):501-515, 1996.
86. Wong R, Wiffen PJ: Bisphosphpnates for the relief of pain secondary to bone metastases (Cochrane Review). Cochrane Database Syst Rev 2002(2):CD002068.
87. Strang P: Analgesic effect of bisphosphonates on bone pain in breast cancer patients: A review article. Acta Oncol 5(50):50-54, 1996.
88. Li EC, Davis LE: Zoledronic acid: A new parenteral bisphosphonate. Clin Ther 25(11):2669-2708, 2003.
89. Menssen HD, Sakalova A, Fontana A, etal: Effects of long-term intravenous ibandronatetherapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma. J Clin Oncol 20(9):2353-2359, 2002.
90. Tripathy D, Lichinitzer M, Lazarev A, et al: Oral ibandronate for the treatment of metastatic bone disease in breast cancer: Efficacy and safety results from a randomized, double-blind, placebo-controlled trial. Ann Oncol 15(5):743-750, 2004.
91. Robinson RG, Preston DF, Schiefelbein M, et al: Strontium 89 therapy for the palliation of pain due to osseous metastases. JAMA 274(5):420-424, 1995.
92. Gunawardana DH, Lichtenstein M, Better N, et al: Results of strontium-89 therapy in patients with prostate cancer resistant to chemotherapy. Clin Nucl Med 29(2):81-85, 2004.
93. Porter AT, McEwan AJ, Powe JE, et al: Results of a randomized phase-Ill trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 25(5):805-813, 1993.
94. Smeland S, Erikstein B, Aas M, et al: Role of strontium-89 as adjuvant to palliative external beam radiotherapy is questionable: Results of a double-blind randomized study. Int J Radiat Oncol Biol Phys 56(5):1397-1404, 2003.
95. Schmeler K, Bastin K: Strontium-89 for symptomatic metastatic prostate cancer to bone: recommendations for hospice patients. Hasp J 11(2):1-10, 1996.
96. Wang RF, Zhang CL, Zhu SL, et al: A comparative study of samarium-153-ethylenediaminetetramethylene phosphonic acid with pamidronate disodium in the treatment of patients with painful metastatic bone cancer. MedPrinc Pract 12(2):97-101, 2003.
97. Sartor O, Reid RH, Hoskin PJ, et al: Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology 63(5):940-945, 2004.
98. Palmedo H, Manka-Waluch A, Albers P, et al: Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: Randomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxy- ethylidenediphosphonate. J Clin Oncol 21(15):2869-2875, 1003.
99. Paulson DF: Oxybutynin chloride in control of post-trasurethral vesical pain and spasm. Urology 11(3):237-238, 1978.
100. Baert L: Controlled double-blind trail of flavoxate in painful conditions of the lower urinary tract. Curr Med Res Opin 2(10):631-635, 1974.
101. Milani R, Scalambrino S, Carrera S, et al: Flavoxate hydrochloride for urinary urgency after pelvic radiotherapy: Comparison of 600mg versus 1200 mg daily dosages. J Int Med Res 16(1):71-74, 1988.
102. Abrams P, Fenely R: The action of prostaglandins on smooth muscle of the human urinary tract in vitro. Br J Urol 47:909-915,1975.
103. Lazzeri M, Beneforti P, Benaim G, et al: Intravesical capsaicin for treatment of severe bladder pain: A randomized placebo controlled study. J Urol 156(3):947-952, 1996.
104. Barbanti G, Maggi CA, Beneforti P, et al: Relief of pain following intravesical capsaicin in patients with hypersensitive disorders of the lower urinary tract. Br J Urol 71(6):686-691, 1993.
105. Eckardt VF, Dodt O, Kanzler G, et al: Treatment of proctalgia fugax with salbutamol inhalation. Am J Gastroenterol 91(4):686-689, 1996.
106. Boquet J, Moore N, Lhuintre JP, et al: Diltiazem for proctalgia fugax [letter]. Lancet 1(8496): 1493, 1986.
107. Castell DO: Calcium-channel blocking agents for gastrointestinal disorders. Am J Cardiol 55(3):210B-213B, 1985.
108. Swain R: Oral clonidine for proctalgia fugax. Gut 28(8):1039-104O, 1987.
109. Patt RB, Proper G, Reddy S: The neuroleptics as adjuvant analgesics. J Pain Symptom Manage 9(7):446-453, 1994
110. Hanks GW: Psychotropic drugs. Postgrad Med J 60(710):881-885, 1984.
111. Ventafridda V, Ripamonti C, Caraceni A, et al: The management of inoperable gastrointestinal obstruction in terminal cancer patients. Tumori 76(4):389-393, 1990.
112. De Conno F, Caraceni A, Zecca E, et al: Continuous subcutaneous infusion of hyos-cine butylbromide reduces secretions in patients with gastrointestinal obstruction. J Pain Symptom Manage 6(8):484-486, 1991.
113. Baines MJ: ABC of palliative care. Nausea, vomiting, and intestinal obstruction. BrAfo/J315(7116):1148-1150, 1997.
114. Baines MJ: Management of intestinal obstruction in patients with advanced cancer. Ann Acad Med Singapore 23(2):178-182,1994.
115. Dean A: The palliative effects of octreotide in cancer patients. Chemotherapy 47(suppl 2):54-6I, 2001.
116. Ripamonti C, Panzeri C, Groff L, et al: The role of somatostatin and octreotide in bowel obstruction: Pre-clinical and clinical results. Tumori 87(1):1-9, 2001.
117. Spiegel D, Moore R: Imagery and hypnosis in the treatment of cancer patients. Oncology (Huntingt) 11(8): 1179-1189 (discussion1189-1195), 1997.
118. Dalton JA, Keefe FJ, Carlson J, et al: Tailoring cognitive-behavioral treatment for cancer pain. Pain Manag Nurs 5(1):3-18,2004.
119. Pan CX, Morrison RS, Ness J, et al: Complementary and alternative medicine in the management of pain, dyspnea, and nausea and vomiting near the end of life. A systematic review. J Pain Symptom Manage 20(5):374-387, 2000.
120. Mondry TE, Riffenburgh RH, Johnstone PA: Prospective trial of complete decongestive therapy" for upper extremity lymphedema after breast cancer therapy. Cancer J 2004;10(1):42-48 (discussion 17-19), 2004.
121. Kligman L, Wong RK, Johnston M, et al: The treatment of lymphedema related to breast cancer: A systematic review and evidence summary. Support Care Cancer 12:6, 421-431, 2004.
122. Carroll D, Moore RA, McQuay HJ, et al: Transcutaneous electrical nerve stimulation (TENS) for chronic pain. Cochrane Database Syst Rev 2001(3):CD003222.
123. Sluka KA, Walsh D: Transcutaneous electrical nerve stimulation: Basic science mechanisms and clinical effectiveness. J Pain 4(3):109-121, 2003.
124. Smith TJ, Staats PS, DeerT, et al: Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: Impact on pain, drug-related toxicity, and survival. J Clin Oncol 20(19):4040-4049,2002.
125. Brose WG, Tanelian DL, Brodsky JB, et al: CSF and blood pharmacokinetics of hydromorphone and morphine following lumbar epidural administration. Pain 45(1):11-15, 1991.
126. Nitescu P, Sjoberg M, Appelgren L, et al: Complications of intrathecal opioids and bupivacaine in the treatment of "refractory" cancer pain. Clin J Pain 11(1):45-62, 1995.
127. Sjoberg M, Nitescu P, Appelgren L, et al: Long-term intrathecal morphine and bupivacaine in patients with refractory cancer pain. Results from a morphine:bupivacaine dose regimen of 0.5:4.75 mg/mL. Anesthesiology 80(2):284-297, 1994.
128. Mercadante S: Intrathecal morphine and bupivacaine in advanced cancer pain patients implanted at home. J Pain Symptom Manage 9(3):201-207, 1994.
129. Eisenach JC, DuPen S, Dubois M, et al: Epidural clonidine analgesia for intractable cancer pain. The Epidural Clonidine Study Group. Pain 61(3):391-399, 1995.
130. Penn RD, Paice JA, Kroin JS; Octreotide: A potent new non-opiate analgesic for intrathecal infusion [see comments]. Pain 49(1):13-19, 1992.
131. Yang CY. Wong CS, Chang JY, et al: Intrathecal ketamine reduces morphine requirements in patients with terminal cancer pain. Can J Anaesth 43(4):379-383, 1996.
132. Yaksh TL: Epidural ketaminerA useful, mechanistically novel adjuvant for epidural morphine? Reg Anesth 21(6):508-513,1996.
133. Blanchard J, Menk E, Ramamurthy S, et al: Subarachnoid and epidural calcitonin in patients with pain due to metastatic cancer. J Pain Symptom Manage 5(1):42-45, 1990.
134. Karavelis A, Foroglou G, Selviaridis P, et al: Intraventricular administration of morphine for control of intractable cancer pain in 90 patients. Neurosurgery 39(1):57-61, 1996.
135. Cramond T, Stuart G: Intraventricular morphine for intractable pain of advanced cancer. J Pain Symptom Manage 8(7):465-173, 1993.
136. Dennis GC, DeWitty RL: Long-term intraventricular infusion of morphine for intractable pain in cancer of the head and neck. Neurosurgery 26(3):404-407 (discussion 407-408), 1990.
137. Symreng T, Gomez MN, Rossi N: Intrapleural bupivacaine v saline after thoracotomy, effects on pain and lung function-A double-blind study [see comments]. J Cardiothorac Anesth 3(2):144-149, 1989.
138. Dionne C: Tumour invasion of the brachial plexus: Management of pain with intrapleural analgesia [letter]. Can J Anaesth 39(5pt 1):520-521, 1992.
139. Lema MJ, Myers DP, De Leon-Casasola O, et al: Pleural phenol therapy for the treatment of chronic esophageal cancer pain. Reg Anesth 17(3):166-170, 1992.
140. Cooper MG, Keneally JP, Kinchington D: Continuous brachial plexus neural blockade in a child with intractable cancer pain. J Pain Symptom Manage 9(4):277-281, 1994.
141. Caraceni A, Portenoy RK: Pain management in patients with pancreatic carcinoma. Cancer 78(3):639-653, 1996.
142. Eisenberg E, Carr DB, Chalmers TC: Neurolytic celiac plexus block for treatment of cancer pain: A meta-analysis [published erratum appears in Anesth Analg 81(1):213,1995]. Anesth Analg 80(2):290-295, 1995.
143. Wong GY, Schroeder DR, Cams PE, et al: Effect of neurolytic celiac plexus block on pain relief, quality of life, and survival in patients with unresectable pancreatic cancer: A randomized controlled trial. JAMA 291(9): 1092-1099, 2004.
144. Kawamata M, Ishitani K, Ishikawa K, et al: Comparison between celiac plexus block and morphine treatment on quality of life in patients with pancreatic cancer pain. Pain 64(3):597-602, 1996.
145. Mercadante S. Celiac plexus block versus analgesics in pancreatic cancer pain. Pain 52(2):187-192, 1993.
146. Gress F, Schmitt C, Sherman S, et al: Endoscopic ultrasound-guided celiac plexus block for managing abdominal pain associated with chronic pancreatitis: A prospective single center experience. Am J Gastroenterol 96(2):409-416, 2001.
147. Wiersema MJ, Wong GY, Croghan GA: Endoscopic technique with ultrasound imaging for neurolytic celiac plexus block. Reg Anesth Pain Med 26(2):159-163, 2001.
148. Plancarte R, de Leon-Casasola OA, et al: Neurolytic superior hypogastric plexus block for chronic pelvic pain associated with cancer. Reg Anesth 22(6):562-568, 1997.
149. Plancarte R, Amescua C, Patt RB, et al: Superior hypogastric plexus block for pelvic cancer pain. Anesthesiology 73(2):236-239, 1990.
150. Plancarte R, Velazquez R, Patt RB: Neurolytic block of the sympathetic axis, in Patt RB (ed): Cancer Pain, pp 377-524. Philadelphia, Lippincott, 1993.
151. Wemm K, Jr, Saberski L: Modified approach to block the ganglion impar (ganglion of Walther) [letter]. Reg Anesth 20(6):544-545, 1995.
152. Nebab EG, Florence IM. An alternative needle geometry for interruption of the ganglion impar [letter]. Anesthesiology 1997; 86(5):1213-1214
153. Lamacraft G, Cousins MJ: Neural blockade in chronic and cancer pain. Int Aneslhesiol Clin 35(2):131-153, 1997.
154. Patt RB, Reddy S: Spinal neurolysis for cancer pain: indications and recent results. Ann Acad Med Singapore 23(2):216-220, 1994.
155. Saris SC, Silver JM, Vieira JF, et al: Sacrococcygeal rhizotomy for perineal pain. Neurosurgery 19(5):789-793, 1986
156. Ischia S, Luzzani A, Polati E:Retrogasserian glycerol injection: A retrospective study of 112 patients. Clin J Pain 6(4):291-296, 1990.
157. Rizzi R, Terrevoli A, Visentin M: Long-term results of alcoholization and thermocoagulation of trigeminal nerve for cancer pain, in Erdmann W, OyamaT, Pemak MJ (eds): The Pain Clinic I. Proceedings of the First International Symposium, p 360. Utrecht, VNU Science Press, 1985.
158. Prasanna A, Murthy PS: Sphenopalatine ganglion block and pain of cancer [letter]. J Pain Symptom Manage 8(3): 125, 1993.
159. Meyer-Witting M, Foster JM: Suprascapular nerve block in the management of cancer pain. Anaesthesia 47(7):626, 1992.
160. Neill RS: Ablation of the brachial plexus. Control of intractable pain, due to a pathological fracture of the humerus. Anaesthesia 34(10):1024-1027, 1979.
161. Stuart G, Cramond T: Role of percutaneous cervical cordotomy for pain of malignant origin. MedJAust 158(10):667-670, 1993.
162. Sanders M, Zuurmond W: Safety of unilateral and bilateral percutaneous cervical cordotomy in 80 terminally ill cancer patients. J Clin Oncol 13(6):1509-1512, 1995.
163. Cowie RA, Hitchcock ER: The late results of antero-lateral cordotomy for pain relief. Acta Neurochir (Wien) l(2):39-50, 1982.
164. Chevrolet JC, Reverdin A, Suter PM, et al: Ventilatory dysfunction resulting from bilateral anterolateral high cervical cordotomy. Dual beneficial effect of aminophylline. Chest 84(1):112-115, 1983.
165. Polatty RC, Cooper KR: Respiratory failure after percutaneous cordotomy. South MedJ79 (7):897-899, 1986.
166. Cherny NI, Portenoy RK: Sedation in the management of refractory symptoms: Guidelines for evaluation and treatment. J Palliat Care 10(2):31-38, 1994.
167. Burt RA: The Supreme Court speaks-Not assisted suicide but a constitutional right to palliative care. N Engl J Med 337(17): 1234-1236, 1997.
168. President's Commission for the Study of Ethical Problems in Medical and Biomedical and Behavioral Research: Deciding to Forgo Life Sustaining Treatment: Ethical and Legal Issues in Treatment Decisions. Washington, US GPO, 1983.
169. American Medical Association: Good care of the dying patient. Council on Scientific Affairs, American Medical Association. JAMA 1996;275(6):474-478, 1996.